文献速递前列腺癌

有前列腺癌家族史的低级别前列腺癌男性可否选择主动监测:来自大型单中心系列的结果

Is Active Surveillance an Option for the Management of Men with Low-grade Prostate Cancer and a Positive Family History? Results from a Large, Single-institution Series.
PubMed 文献 · Eur Urol Oncol · 2023-03-31

该单中心系列纳入656例GG1前列腺癌主动监测患者,其中119例(18%)有家族史。家族史与随访活检重新分级至GG≥2相关(HR 1.60,95%CI 1.19-2.15,p=0.002),5年无重新分级生存率家族史组39% vs 无家族史组57%(p=0.006)。在家族史患者中,PSA密度、高体积GG1和MRI可疑是重新分级的预测因素。

要点

  • 家族史患者5年无重新分级生存率为39%,无家族史者为57%(p=0.006)。
  • 家族史与重新分级至GG≥2相关(HR 1.60,95%CI 1.19-2.15,p=0.002)。
  • 家族史患者中PSA密度、高体积GG1和MRI可疑预测重新分级(HR分别为2.87、3.04、3.87,均p<0.05)。

核心结论

  • 有家族史的主动监测患者重新分级风险增加。
  • MRI阴性、低疾病体积和低PSA密度可识别重新分级风险低的家族史患者。
  • 样本量和宽置信区间提示基于这些结果得出结论需谨慎。

研究设计与样本

  • 单中心主动监测方案纳入656例GG1前列腺癌患者。
  • 采用Kaplan-Meier分析评估重新分级时间,多变量Cox回归检验家族史对重新分级的影响。
  • 197例接受延迟根治性前列腺切除术,64例接受外照射放疗,评估家族史对肿瘤学结局的影响。

主要发现

  • 119例(18%)有家族史,中位随访54个月(四分位距29-84个月),264例发生重新分级。
  • 5年无重新分级生存率家族史组39% vs 无家族史组57%(p=0.006)。
  • 家族史与重新分级至GG≥2相关(HR 1.60,95%CI 1.19-2.15,p=0.002)。
  • 家族史患者中,PSA密度、高体积GG1(≥33%穿刺针受累或任一针≥50%受累)和MRI可疑预测重新分级(HR分别为2.87、3.04、3.87,均p<0.05)。
  • 家族史与不良病理特征及生化复发无关联(均p>0.05)。

临床怎么用

  • 作者认为,有家族史的患者重新分级风险显著增加,但延迟治疗后的肿瘤学结局无不良影响,需与这些患者谨慎讨论,但不排除初始期待管理。

局限性

  • 样本量和宽置信区间提示基于这些结果得出结论需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Family history (FH) of prostate cancer (PCa) is associated with an increased risk of PCa and adverse disease features. However, whether patients with localized PCa and FH could be considered for active surveillance (AS) remains controversial. OBJECTIVE: To assess the association between FH and reclassification of AS candidates, and to define predictors of adverse outcomes in men with positive FH. DESIGN, SETTING, AND PARTICIPANTS: Overall, 656 patients with grade group (GG) 1 PCa included in an AS protocol at a single institution were identified. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier analyses assessed the time to reclassification (GG ≥2 and GG ≥3 at follow-up biopsies) overall and according to FH status. Multivariable Cox regression tested the impact of FH on reclassification and identified the predictors among men with FH. Men treated with delayed radical prostatectomy (n = 197) or external-beam radiation therapy (n = 64) were identified, and the impact of FH on oncologic outcomes was assessed. RESULTS AND LIMITATIONS: Overall, 119 men (18%) had FH. The median follow-up was 54 mo (interquartile range 29-84 mo), and 264 patients experienced reclassification. The 5-yr reclassification-free survival rate was 39% versus 57% for FH versus no FH (p = 0.006), and FH was associated with reclassification to GG ≥2 (hazard ratio [HR] 1.60, 95% confidence interval [CI] 1.19-2.15, p = 0.002). In men with FH, the strongest predictors of reclassification were prostate-specific antigen (PSA) density (PSAD), high-volume GG 1 (≥33% of cores involved or ≥50% of any core involved), and suspicious magnetic resonance imaging (MRI) of the prostate (HRs 2.87, 3.04, and 3.87, respectively; all p < 0.05). No association between FH, adverse pathologic features, and biochemical recurrence was observed (all p > 0.05). CONCLUSIONS: Patients with FH on AS are at an increased risk of reclassification. Negative MRI, low disease volume, and low PSAD identify men with FH and a low risk of reclassification. Nonetheless, sample size and wide CIs entail caution in drawing conclusions based on these results. PATIENT SUMMARY: We tested the impact of family history in men on active surveillance for localized prostate cancer. A significant risk of reclassification, but not adverse oncologic outcomes after deferred treatment, prompts the need for cautious discussion with these patients, without precluding initial expectant management.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Leni R, Gandaglia G, Stabile A, et al. Is Active Surveillance an Option for the Management of Men with Low-grade Prostate Cancer and a Positive Family History? Results from a Large, Single-institution Series. Eur Urol Oncol. 2023. PMID: 37005213. doi:10.1016/j.euo.2023.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。